CPC A61M 5/007 (2013.01) [A61K 51/121 (2013.01); A61K 51/1282 (2013.01); A61M 5/142 (2013.01); A61M 5/1408 (2013.01); A61M 5/162 (2013.01); A61M 5/16827 (2013.01); A61M 5/16881 (2013.01); A61N 5/1007 (2013.01); G01T 1/20 (2013.01); G01T 7/005 (2013.01); G21F 5/015 (2013.01); G21G 1/0005 (2013.01); G21G 4/08 (2013.01); G21H 5/02 (2013.01); A61K 2123/00 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3313 (2013.01); A61M 2205/3389 (2013.01); A61M 2205/702 (2013.01); A61N 2005/1021 (2013.01); G01T 1/1603 (2013.01); G21G 2001/0031 (2013.01)] | 22 Claims |
1. An infusion system comprising:
a frame that carries a beta detector, a gamma detector, an eluate-receiving container, and a waste container and is further configured to receive a radioisotope generator that generates radioactive eluate via elution,
wherein the beta detector is positioned to measure beta emissions emitted from the radioactive eluate, and
the gamma detector is positioned to measure gamma emissions emitted from a portion of the radioactive eluate received in the eluate receiving container to evaluate a safety of the radioactive eluate delivered by the infusion system to ensure that the radioactive eluate generated by the radioisotope generator is safe for patient infusion.
|